Skip to main content

Table 2 Asymptomatic shedding of HSV-1 detected by PCR from mouth swabs (saliva) of healthy subjects

From: HSV-1 latent rabbits shed viral DNA into their saliva

Authors, Year

N

Individuals: total positive/total subjects

Shedding frequency: total positiveswabs/total swabs

Mouth swab frequency: numberof swabs/subject

Robinson et al., 1992 [65]

12

12/12 (100%)

0/0 (0%)

0

Robinson et al., 1992 [65]

12*

0/12 (0%)

0/0 (0%)

0

Tateishi et al., 1994 [63]

1000

46/1000 (4.6%)

46/1000 (4.6%)

one

Kriesel et al., 1994 [66]

27

3/27 (11%)

3/27 (11%)

one

Lee et al., 1996 [67]

87

12/87 (13.8%)

12/87 (13.8%)

one

Knaup et al., 2000 [68]

30

19/30 (63.3%)

39/290 (13.5%)

9-10

Druce et al., 2002 [69]

477

43/477 (9%)

43/477 (9%)

one

Gleeson et al., 2002 [70]

14

0/14 (0%)

0/0 (0%)

0

Youssef et al., 2002 [71]

5

1/5 (20%)

1/5 (20%)

one

Miller et al., 2004 [72]

123

11/123 (8.9%)

11/123 (8.9%)

one

Miller et al., 2004 [72]

63**

13/63 (21%)

17/217 (7.8%)

3-4

Kaufman et al., 2005 [73]

50

46/50 (92%)

1020/2712 (37.6%)

54

Miller et al., 2005 [74]

58

1/58 (1.7%)

1/58 (1.7%)

one

da Silva et al., 2005 [75]

25

25/25 (100%)

162/309(52.4%)

12-13

Lin et al., 2005 [76]

60

4/60 (6.7%)

4/60 (6.7%)

one

Kumar et al., 2009 [77]

14*****

12/14 (86%)

357/840 (42%)

60

Kumar et al., 2009 [77]

15***

15/15 (100%)

465/900 (52%)

60

Kumar et al., 2009 [77]

16****

15/16 (94%)

701/961 (73%)

60

Totals

2076

278/2088 (13%)

2882/8066 (36%)

 
  1. *Had no clinical history of HSV-1.
  2. **Had dental procedure prior to mouth swab.
  3. *** Received Valtrex treatment + Placebo treatment.
  4. ****Received Valtrex treatment + Aspirin treatment.
  5. ***** Received 2 Placebo treatments.
  6. The Kumar et al., 2009 study was double blind. Placebo and control had trials in healthy adults.